Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series
Open Access
- 4 July 2022
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 122, 953-956
Abstract
No abstract availableKeywords
Funding Information
- Pacira Pharmaceuticals
This publication has 11 references indexed in Scilit:
- Treatment of Mycobacterium abscessus Pulmonary DiseaseChest, 2022
- In Vitro Susceptibility Testing of Omadacycline against Nontuberculous MycobacteriaAntimicrobial Agents and Chemotherapy, 2021
- Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus InfectionsOpen Forum Infectious Diseases, 2021
- Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case SeriesOpen Forum Infectious Diseases, 2020
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineClinical Infectious Diseases, 2020
- Omadacycline in the Treatment of Mycobacterium abscessus InfectionClinical Infectious Diseases, 2019
- Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trialThe Lancet Infectious Diseases, 2019
- Non-tuberculous mycobacterial pulmonary diseaseEuropean Respiratory Journal, 2019
- Treatment of Mycobacterium abscessus ComplexSeminars in Respiratory and Critical Care Medicine, 2018
- Lack of Adherence to Evidence-based Treatment Guidelines for Nontuberculous Mycobacterial Lung DiseaseAnnals of the American Thoracic Society, 2014